Literature DB >> 9179558

Ciprofloxacin decreases plasma phenytoin concentrations in the rat.

M S al-Humayyd1.   

Abstract

The pharmacokinetic interaction between phenytoin and ciprofloxacin was studied in rats. One group of animals was given phenytoin (20 mg/kg, p.o.) as a single daily dose for 7 days. In another group of animals, the same protocol was followed except that ciprofloxacin was given in two equal doses (15 mg/kg, i.p., each) on days 5, 6 and 7. On day 8, phenytoin blood sampling was performed at 0.083, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0 and 12.0 h. Similarly, urine samples were collected at 4, 6 and 8 h following drug administration from the same animals that had received either phenytoin alone or phenytoin together with ciprofloxacin. The concentrations of phenytoin in the plasma and urine were measured using an HPLC method. Ciprofloxacin significantly (P < 0.05) reduced the area under the curve (AUC), the maximum plasma concentration (Cmax) and the elimination half-life (t1/2) of phenytoin. Additionally, ciprofloxacin increased phenytoin concentrations in urine at 4, 6 and 8 h. These results show that ciprofloxacin decreases the plasma levels of phenytoin when the two drugs are given concurrently.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179558     DOI: 10.1007/BF03189782

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  24 in total

1.  A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.

Authors:  G Arcieri; E Griffith; G Gruenwaldt; A Heyd; B O'Brien; P Screen; N Becker; R August
Journal:  J Clin Pharmacol       Date:  1988-02       Impact factor: 3.126

2.  Analysis of serum concentration of phenobarbital, phenytoin, carbamazepine and carbamazepine 10,11-epoxide by solvent-recycled liquid chromatography.

Authors:  A Asberg; F Haffner
Journal:  Scand J Clin Lab Invest       Date:  1987-06       Impact factor: 1.713

3.  Effect of ciprofloxacin on the pharmacokinetics of multiple-dose phenytoin serum concentrations.

Authors:  M L Job; S K Arn; J G Strom; N F Jacobs; M J D'Souza
Journal:  Ther Drug Monit       Date:  1994-08       Impact factor: 3.681

4.  Ciprofloxacin therapy in cystic fibrosis.

Authors:  B E Scully; M Nakatomi; C Ores; S Davidson; H C Neu
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

5.  Double-blind comparison of ciprofloxacin with cefotaxime in the treatment of skin and skin structure infections.

Authors:  J A Pérez-Ruvalcaba; N P Quintero-Pérez; J J Morales-Reyes; J A Huitrón-Ramírez; J J Rodríguez-Chagollán; E Rodríguez-Noriega
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

Review 6.  Pharmacokinetics in the elderly. Studies on ciprofloxacin.

Authors:  M Lebel; M G Bergeron
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

Review 7.  Pharmacokinetics and interactions of antiepileptic drugs.

Authors:  N M Graves
Journal:  Am J Hosp Pharm       Date:  1993-12

8.  Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes.

Authors:  U Fuhr; T Wolff; S Harder; P Schymanski; A H Staib
Journal:  Drug Metab Dispos       Date:  1990 Nov-Dec       Impact factor: 3.922

9.  Co-administration of ciprofloxacin and cyclosporin: lack of evidence for a pharmacokinetic interaction.

Authors:  K K Tan; A K Trull; S Shawket
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

Review 10.  Effects of antacids on the clinical pharmacokinetics of drugs. An update.

Authors:  R Gugler; H Allgayer
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.